Protagenic Therapeutics

Protagenic Therapeutics Current Liabilities

The Current Liabilities of Protagenic Therapeutics (PTIX) as of Nov 16, 2026 is 5.04 M USD. In the previous year, Current Liabilities was 1.05 M USD — a change of 382.15% (higher).

Current Liabilities

5.04 MUSD

YoY

382.15%

Last updated:

Current Liabilities of Protagenic Therapeutics is 2025 5.04 M USD. Current Liabilities of Protagenic Therapeutics was 2024 1.05 M USD. It decreases by 382.15% higher compared to the previous year.

The Protagenic Therapeutics Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
907,767.00 USD
Jan 1, 2019
1.36 M USD
Jan 1, 2020
795,187.00 USD
Jan 1, 2021
1.27 M USD
Jan 1, 2022
1.28 M USD
Jan 1, 2023
769,052.00 USD
Jan 1, 2024
1.05 M USD
Jan 1, 2025
5.04 M USD
The Protagenic Therapeutics Current Liabilities history
YEARCurrent LiabilitiesYoY
5.04 MUSD+382.15%
1.05 MUSD+35.98%
769,052.00USD-39.91%
1.28 MUSD+1.12%
1.27 MUSD+59.17%
795,187.00USD-41.41%
1.36 MUSD+49.52%
907,767.00USD+61.61%
561,692.00USD-17.98%
684,857.00USD+262.36%
189,000.00USD-0.53%
190,000.00USD+35.71%
140,000.00USD-99.23%
18.18 MUSD+19.93%
15.16 MUSD-40.37%
25.42 MUSD-31.17%
36.93 MUSD+268.74%
10.02 MUSD+89.90%
5.27 MUSD+3,002.50%
170,000.00USD+88.89%
90,000.00USD-79.07%
430,000.00USD-95.09%
8.76 MUSD+1.15%
8.66 MUSD-10.81%
9.71 MUSD+13.17%
8.58 MUSD-11.18%
9.66 MUSD+28.12%
7.54 MUSD+205.26%
2.47 MUSD-50.89%
5.03 MUSD+40.90%
3.57 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Protagenic Therapeutics Stock analysis

What does Protagenic Therapeutics do? Protagenic Therapeutics, Inc. develops therapeutics for stress-related neuropsychiatric and mood disorders. Its lead compound PT00114 is a synthetic TCAP-1 peptide designed to dampen overactive stress responses. The company also has a portfolio of earlier stage neuropeptides targeting the TCAP pathway in preclinical evaluation. PT00114 has shown pre-clinical efficacy in animal models of depression, anxiety, substance abuse, addiction, and PTSD, including the Saleens test for opioid withdrawal. The company focuses on developing treatments for conditions where current therapies are limited or ineffective. Protagenic's products are developed for pharmaceutical companies and research institutions seeking novel treatments for neuropsychiatric disorders. The target segments include patients suffering from depression, anxiety, PTSD, and substance abuse disorders. The company's lead compound PT00114 and its neuropeptide portfolio are positioned as potential treatments for these conditions, with the aim of addressing unmet medical needs in mental health care. Protagenic Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Protagenic Therapeutics stock

Current Liabilities of Protagenic Therapeutics is 5.04 M USD in 2025.

Current Liabilities of Protagenic Therapeutics changed from 1.05 M USD to 5.04 M USD, representing a 382.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Protagenic Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Protagenic Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Protagenic Therapeutics

All Key Metrics — Protagenic Therapeutics